Rivastigmine in Alzheimer's disease: Cognitive function and quality of life

Roberta Annicchiarico, Alessia Federici, Carla Pettenati, Carlo Caltagirone

Research output: Contribution to journalArticlepeer-review


Alzheimer's disease (AD) is a chronic neurodegenerative disorder characterized by a progressive loss of cognitive and functional abilities associated with various behavioral disturbances. Its impact on public health and society as a whole is devastating. Slowing of the cognitive impairment, and improvements in disease duration, self-sufficiency and behavioral disturbances represent the best outcomes of pharmacologic therapy. Cholinesterase inhibitors (ChE-I) have been shown to be effective in treating the cognitive, behavioral, and functional deficits of AD. Rivastigmine is a dual inhibitor of both acetylcholine esterase (AChE) and butyrylcholinesterase (BuChE), enzymes involved in the hydrolysis of acetylcholine. Although this drug has been shown to be beneficial in patients with AD, its benefits are limited and their long-term effectiveness has not been well demonstrated.

Original languageEnglish
Pages (from-to)1113-1123
Number of pages11
JournalTherapeutics and Clinical Risk Management
Issue number6
Publication statusPublished - 2007


  • Alzheimer's disease
  • Drugs
  • Therapy

ASJC Scopus subject areas

  • Chemical Health and Safety
  • Medicine(all)
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research


Dive into the research topics of 'Rivastigmine in Alzheimer's disease: Cognitive function and quality of life'. Together they form a unique fingerprint.

Cite this